Upgrade to SI Premium - Free Trial

Madrigal Pharma (MDGL)

471.82 +4.28 (0.92%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 October 20, 2026 8:01 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) October 15, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS October 14, 2026 6:49 AM - StreetInsider Madrigal publishes Rezdiffra genetic subgroup data in liver journal October 6, 2026 8:05 AM - StreetInsider Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants October 6, 2026 8:00 AM - Globe NewsWire Goldman Sachs Assumes Madrigal Pharmaceuticals (MDGL) at Buy September 24, 2026 5:00 AM - StreetInsider Citi initiates Madrigal Pharmaceuticals coverage with Buy rating September 23, 2026 5:03 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) September 16, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 20, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals adds J&J executive to its board August 12, 2026 8:00 AM - StreetInsider Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors August 12, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 6, 2026 4:06 PM - Globe NewsWire Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference August 6, 2026 8:01 AM - Globe NewsWire Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform August 4, 2026 5:07 AM - StreetInsider Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays August 3, 2026 6:40 AM - StreetInsider Madrigal Pharma (MDGL) Tops Q2 EPS by 76c July 31, 2026 9:18 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL) July 31, 2026 6:42 AM - StreetInsider Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays July 31, 2026 6:12 AM - StreetInsider Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates July 30, 2026 7:00 AM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $587 at Canaccord July 29, 2026 6:43 AM - StreetInsider Wells Fargo Starts Madrigal Pharmaceuticals (MDGL) at Overweight July 27, 2026 5:44 AM - StreetInsider Full Article List